News
Celcuity gets FDA nod for first-in-class breast cancer drug
Celcuity has won FDA approval for gedatolisib – its first product – as a treatment for patients with a particular form of breast cancer.
News
Digital check-ins improve cancer care and reduce inequality
A study has shown that, for people living with advanced cancer, a weekly remote check-in with the care team can have a significant impact on outcomes.
Oncology
ASCO 2026: Pluvicto shows consistency, with Dr Fred Saad
In a conversation at ASCO 2026, Dr Fred Saad of the University of Montreal shared some insights from a subgroup analysis of Pluvicto
News
AstraZeneca adds another Chinese asset, from Dizal
AstraZeneca has continued its pipeline-boosting deal spree in China with a $1.5bn licensing deal for Dizal Pharma's lung cancer therapy Zegfrovy.
Oncology
EGFR-mutant lung cancer: Cracking the drug resistance code
Targeted therapies have transformed the treatment landscape for non-small cell lung cancer (NSCLC) over the past decade.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
